用双价小分子重新连接了Ewing肉瘤中EWS/FLI1聚变蛋白
bioRxiv : the preprint server for biology
|April 1, 2025
概括
研究人员开发了EB-TCIP,这是一种新的小分子,其向癌症驱动的融合转录因子,如EWS/FLI1. 这种方法重新连接转录以潜在地治疗儿科恶性瘤.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 由融合转录因子驱动的放松转录在儿科癌症中很常见.
- 针对转录因子是困难的,因为它们缺乏可用药物的口袋.
- 化学诱导的近距离提供了一种控制基因表达的新策略.
研究的目的:
- 开发一种新的小分子,EB-TCIP,用于针对Ewing肉瘤中的EWS/FLI1.
- 为了证明化学诱导的近距离对于重新连接聚变转录因子的潜力.
- 探索由异常转录驱动的儿科恶性瘤的新治疗途径.
主要方法:
- 开发一种双价小分子,EB-TCIP.
- 招募FKBP12标记的EWS/FLI1到BCL6结合的DNA位点.
- 评估BCL6标基因表达和三元复合体的形成.
主要成果:
- EB-TCIP成功地将FKBP-EWS/FLI1招募到特定的DNA部位.
- 观察到BCL6基因的快速表达.
- 该分子的活性取决于三元复合体的形成和FKBP-EWS/FLI1.1的细胞特异表达.
结论:
- EWS/FLI1可以有效地在染色质上重新定位,以诱导基因表达.
- 这项概念验证研究验证了双价分子用于向融合转录因子的使用.
- 这些发现为开发针对由异常转录驱动的癌症的新疗法提供了基础.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K


